Copper Cu 64 PSMA I&T not checked

Curium US LLC

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
1 active
2 in total · 1 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“Radiopharmaceutical PET imaging tracer injected intravenously for staging of prostate cancer.”In the company’s words, NCT06235151 on ClinicalTrials.gov
Tested for
Prostate Cancer, Prostate Adenocarcinoma
Main trialPhase 3
“This is a prospective, open-label Phase 3 study to evaluate copper Cu 64 PSMA I\&T injection for PET/CT imaging in patients with newly diagnosed unfavorable intermediate high-risk, high-risk or very high-risk prostate cancer.”In the company’s words, NCT06235151 on ClinicalTrials.gov

Other drugs for Prostate Cancer

All 194 drugs for Prostate Cancer

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting Oct 2026 Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
Phase 3Completed 18 Feb 2025 Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate Cancer
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Copper Cu 64 PSMA I&T

Following is part of Solo: you see every change to Copper Cu 64 PSMA I&T the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in